Company intelligence / Profile preview

CoAxia

Minneapolis/Twin Cities, Minnesota, United Statesintercoax.com ↗

Ownership: Private
Employees: ~45
Development stage: Other

Overview

CoAxia developed the NeuroFlo and FloControl catheters to improve cerebral perfusion in patients with acute ischemic stroke and related conditions. The flagship SENTIS trial showed safety and some long-term improvement signals but did not meet its primary efficacy endpoint. The company obtained limited regulatory approvals (FDA HDE, CE Mark) but struggled to secure broader US approval before being acquired by Zoll Medical in mid–2013. Offices closed shortly thereafter.[7]

Therapeutic areas: NeurologyCardiovascular
Modalities: Device (specifically balloon catheter-based devices)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on CoAxia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoAxia.

Explore the full profile